# US 2013/0280755 A1 · Therapeutic methods for solid delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280755 A1
- Document ID: US20130280755A1
- Status: Published application
- Kind: A1
- Application number: 13/988,309
- Filed: 2011-11-23
- Published: 2013-10-24
- Earliest claimed: 2010-11-23
- Assignees: Fred Hutchinson Cancer Research Center
- Inventors: Christopher Hubert
- Web page: https://patentgrep.com/patent/US20130280755A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61M 5/3295: {Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel}
- A61M 37/0015: {by using microneedles}
- A61M 37/0069: {Devices for implanting pellets, e.g. markers or solid medicaments (for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027)}
- A61M 2037/003: {having a lumen}
- A61M 2037/0046: {Solid microneedles}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A fluid-delivery device includes an array of needles. The needle can deposit a hollow and/or porous tube into a tissue of a subject, and the porous tube can contain one or more fluid agents. The hollow and/or porous tube can control the rate at which the agents diffuse into the tissue. The device can simultaneously deliver a plurality of porous tubes along parallel axes in a tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue; based on the evaluation, candidate agents or subjects can be selected or deselected for clinical trials or therapy.

## Claims

### Claim 1

A drug-delivery device for constrained solid delivery of one or more fluid agents to a tissue, comprising:
i) one or more needles each configured to receive a porous tube; and
ii) one or more porous tubes each configured to contain at least one fluid agent.

### Claim 2 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes is biocompatible, permeable, and/or scissile.

### Claim 3 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes comprises polysulfone, polyamine, polyamide, polycarbonate, polycarbamate, polyurethane, polyester, polyether, polyolefin, polyaromatic, polylactic acid, a cross-linked polymer, or a combination or co-polymer of any of the foregoing.

### Claim 4 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes comprises polysulfone.

### Claim 5 (depends on 1)

The drug-delivery device of claim 1, further comprising an actuator configured to push said one or more porous tubes from said one or more needles upon activation.

### Claim 6 (depends on 5)

The drug-delivery device of claim 5, wherein said actuator is a plunger.

### Claim 7 (depends on 1)

The drug-delivery device of claim 1, wherein each of said one or more needles is not permeable to said one or more fluid agents.

### Claim 8 (depends on 1)

The drug-delivery device of claim 1, further comprising two or more reservoirs each in communication with a respective one of said one or more needles.

### Claim 9 (depends on 1)

The drug-delivery device of claim 1, further comprising ten or more reservoirs each in communication with a respective one of said one or more needles.

### Claim 10 (depends on 1)

The drug-delivery device of claim 1, further comprising one hundred or more reservoirs each in communication with a respective one of said one or more needles.

### Claim 11 (depends on 1)

The drug-delivery device of claim 1, comprising two or more porous tubes.

### Claim 12 (depends on 1)

The drug-delivery device of claim 1, comprising five or more porous tubes.

### Claim 13 (depends on 1)

The drug-delivery device of claim 1, comprising ten or more porous tubes.

### Claim 14 (depends on 1)

The drug-delivery device of claim 1, comprising one hundred or more porous tubes.

### Claim 15 (depends on 11, 12, 13, 14)

The drug-delivery device of claim 11-14, wherein none of the porous tubes comprises the same fluid agent as the agent in any other tubes.

### Claim 16 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes comprises two or more different fluid agents.

### Claim 17 (depends on 1)

The drug-delivery device of claim 1, wherein at least two of the porous tubes comprise a same fluid agent.

### Claim 18 (depends on 17)

The drug-delivery device of claim 17, wherein the concentrations of the same fluid agent in different porous tubes are different.

### Claim 19 (depends on 1)

The drug-delivery device of claim 1, wherein said one or more fluid agents are capable of diffusing through the pores at a diffusion rate when the porous tube is embedded in a tissue.

### Claim 20 (depends on 19)

The drug-delivery device of claim 19, wherein the diffusion rates are controlled by the pore size.

### Claim 21 (depends on 20)

The drug-delivery device of claim 20, wherein the pore size of porous tubes is a range between about 1 nm and about 5 micrometers.

### Claim 22 (depends on 1)

The drug-delivery device of claim 1, wherein said one or more fluid agents comprise an anti-cancer agent, an anti-inflammatory agent, an anti-infective agent, a regenerative agent, a relaxing agent, an apoptosis-inhibiting agent, an apoptosis-inducing agent, an anti-coagulatory agent, a dermatological agent, a growth-stimulating agent, a vasodilating agent, a vasorestricting agent, an analgesic agent, or an anti-allergic agents.

### Claim 23 (depends on 1)

The drug-delivery device of claim 1, wherein said one or more fluid agents comprise an anti-cancer agent.

### Claim 24 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes comprises at least one indicator particle.

### Claim 25 (depends on 24)

The drug-delivery device of claim 24, wherein said at least one indicator particle is selected from the group consisting of a metallic particle, a fluorescent dye, a quantum dot, a quantum barcode, a radiographic contrast agent, and a magnetic resonance imaging contrast agent.

### Claim 26 (depends on 24)

The drug-delivery device of claim 24, wherein said at least one indicator particle is a fluorescent dye.

### Claim 27 (depends on 1)

The drug-delivery device of claim 1, wherein said tissue is an animal tissue.

### Claim 28 (depends on 1)

The drug-delivery device of claim 1, wherein said tissue is a human tissue.

### Claim 29 (depends on 1)

The drug-delivery device of claim 1, wherein said tissue is a tumor.

### Claim 30 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes is hollow.

### Claim 31 (depends on 1)

The drug-delivery device of claim 1, wherein at least one of said one or more porous tubes uniformly comprises porous material.

### Claim 32 (depends on 1)

The drug-delivery device of claim 1, comprising two or more needles.

### Claim 33 (depends on 1)

The drug-delivery device of claim 1, comprising five or more needles.

### Claim 34 (depends on 1)

The drug-delivery device of claim 1, comprising ten or more needles.

### Claim 35 (depends on 1)

The drug-delivery device of claim 1, comprising one hundred or more needles.

### Claim 36 (depends on 32, 33, 34, 35)

The drug-delivery device of claim 32-35, wherein none of the needles comprises the same fluid agent as the agent in any other needles.

### Claim 37 (depends on 32, 33, 34, 35)

The drug-delivery device of claim 32-35, wherein at least one of the needles comprises two or more porous tubes.

### Claim 38 (depends on 32, 33, 34, 35)

The drug-delivery device of claim 32-35, wherein at least one of the needles comprises two or more fluid agents.

### Claim 39 (depends on 32, 33, 34, 35)

The drug-delivery device of claim 32-35, wherein at least two of the needles comprise a same fluid agent.

### Claim 40 (depends on 32, 33, 34, 35)

The drug-delivery device of claim 32-35, wherein the concentrations of the same fluid agent in different needles are different.

### Claim 41

A method for spatially restricted solid delivery of one or more fluid agents to a tissue of an organism, comprising the steps of:
i) inserting one or more porous tubes into a tissue using one or more needles; and
ii) delivering the content of said one or more porous tubes to the tissue at least partially by diffusion through pores of said one or more porous tubes.

### Claim 42 (depends on 41)

The method of claim 41, wherein the content of porous tube is delivered solely by diffusion.

### Claim 43 (depends on 41)

The method of claim 41, wherein said inserting is performed with an actuator.

### Claim 44 (depends on 41)

The method of claim 41, wherein said actuator is a plunger

### Claim 45 (depends on 41)

The method of claim 41, further comprising loading said one or more porous tubes with said one or more fluid agents.

### Claim 46 (depends on 45)

The method of claim 45, wherein said loading occurs by passive diffusion or osmosis.

### Claim 47 (depends on 45)

The method of claim 45, wherein said loading occurs by capillary force.

### Claim 48 (depends on 45)

The method of claim 45, wherein said loading occurs by contacting one end of each of said porous tubes to a fluid reservoir, and applying negative pressure to the opposite end of each of said porous tubes.

### Claim 49 (depends on 41)

The method of claim 41, wherein two or more porous tubes are inserted.

### Claim 50 (depends on 41)

The method of claim 41, wherein ten or more porous tubes are inserted.

### Claim 51 (depends on 41)

The method of claim 41, wherein one hundred or more porous tubes are inserted.

### Claim 52 (depends on 49, 50, 51)

The method of claim 49-51, wherein none of the porous tubes comprises the same fluid agent as the agent in any other tubes.

### Claim 53 (depends on 49, 50, 51)

The method of claim 49-51, wherein the porous tubes are inserted along parallel axes within said tissue.

### Claim 54 (depends on 41)

The method of claim 41, wherein at least one of said one or more porous tubes comprises two or more fluid agents.

### Claim 55 (depends on 41)

The method of claim 41, wherein each of said one or more needles is not permeable to said one or more fluid agents.

### Claim 56 (depends on 49, 50, 51)

The drug-delivery device of claim 49-51, wherein at least two of the porous tubes comprise a same fluid agent.

### Claim 57 (depends on 41)

The method of claim 41, wherein at least one of said one or more porous tubes comprises polysulfone.

### Claim 58 (depends on 41)

The method of claim 41, wherein the average pore diameter of pores of said one or more porous tubes is a range between about 1 nm and about 5 micrometers.

### Claim 59 (depends on 41)

The method of claim 41, wherein said one or more fluid agents comprise an anti-cancer agent, an anti-inflammatory agent, an anti-infective agent, a regenerative agent, a relaxing agent, an apoptosis-inhibiting agent, an apoptosis-inducing agent, an anti-coagulatory agent, a dermatological agents, a growth-stimulating agent, an vasodilating agent, a vasorestricting agent, an analgesic agent, or an anti-allergic agent.

### Claim 60 (depends on 41)

The method of claim 41, wherein said one or more fluid agents comprise an anti-cancer agent.

### Claim 61 (depends on 41)

The method of claim 41, wherein said one or more fluid agents are delivered at or below systematically detectable concentration.

### Claim 62 (depends on 41)

The method of claim 41, wherein said tissue comprises a tumor.

### Claim 63 (depends on 62)

The method of claim 62, wherein said tumor comprises at least one cancer cell selected from the group consisting of a leukemia cell, a pancreatic cancer cell, a prostate cancer cell, a breast cancer cell, a colon cancer cell, a lung cancer cell, a brain cancer cell, a glioma cancer cell, a melanoma cell, a renal cancer cell, and an ovarian cancer cell.

### Claim 64 (depends on 41)

The method of claim 41, wherein the porous tube remains in the tissue after the insertion.

### Claim 65 (depends on 41)

The method of claim 41, wherein the delivery duration spans a selected period of time.

### Claim 66 (depends on 65)

The method of claim 65, wherein said selected period of time is at least one minute.

### Claim 67 (depends on 65)

The method of claim 65, wherein said selected period of time is a range between about 1 minute and about 96 hours.

### Claim 68 (depends on 65)

The method of claim 65, wherein said selected period of time is a range between about one week and about six months.

### Claim 69 (depends on 41)

The method of claim 41, further comprising evaluating the effects of said one or more fluid agents on said tissue.

### Claim 70 (depends on 69)

The method of claim 69, wherein the evaluation comprises excising at least one portion of the tissue after introducing said one or more fluid agents.

### Claim 71 (depends on 70)

The method of claim 70, wherein said excising occurs at a selected period of time after introducing said one or more fluid agents.

### Claim 72 (depends on 71)

The method of claim 71, wherein the selected period of time is a range between about 1 minute and about 96 hours.

### Claim 73 (depends on 71)

The method of claim 71, wherein the selected period of time is a period exceeding one week.

### Claim 74 (depends on 71)

The method of claim 71, wherein the selected period of time is a range between about one week and about six months.

### Claim 75 (depends on 69)

The method of claim 69, wherein the evaluation comprises pre-excising at least one portion of the tissue after introducing said one or more fluid agents.

### Claim 76 (depends on 69)

The method of claim 69, wherein the evaluation comprises imaging the tissue.

### Claim 77 (depends on 76)

The method of claim 76, wherein said imaging comprises radiographic imaging, magnetic resonance imaging, positron emission tomogoraphy, and biophotonic imaging.

### Claim 78 (depends on 76)

The method of claim 76, wherein said imaging occurs before, during, or after introduction of said fluid agents.

### Claim 79 (depends on 69)

The method of claim 69, wherein the evaluation comprises detecting an altered physiological state.

### Claim 80 (depends on 69)

The method of claim 69, wherein the evaluation comprises determining and comparing the effects of at least two of the fluid agents on adjacent positions within the region of said tissue.

### Claim 81 (depends on 69)

The method of claim 69, wherein the evaluation comprises determining the effects of at least two of the fluid agents on a same position within the region of said tissue.

### Claim 82 (depends on 69)

The method of claim 69, wherein the evaluation comprises determining the effects of at least one of the fluid agents along the axis of insertion within the region of said tissue.

### Claim 83

A method of rating a candidate agent for development into a therapeutic agent, comprising the steps of:
i) inserting one or more porous tubes containing one or more candidate agents into a tissue using one or more needles;
ii) delivering the content of said one or more porous tubes into the tissue at least partially by diffusion through pores of said one or more porous tubes; and
iii) evaluating the effects of said one or more candidate agents on the tissue.

### Claim 84 (depends on 83)

The method of claim 83, further comprising one of (i) selecting at least one of said agents based on said evaluation; (ii) deselecting at least one of said agents based on said evaluation; and (iii) prioritizing at least two of said agents based on said evaluating.

### Claim 85 (depends on 83)

The method of claim 83, wherein said one or more candidate agents are delivered at or below systematically detectable concentration.

### Claim 86 (depends on 83)

The method of claim 83, wherein said tissue is a tumor.

### Claim 87 (depends on 83)

The method of claim 83, wherein said one or more candidate agents comprise at least one position marker.

### Claim 88 (depends on 83)

The method of claim 83, wherein said one or more candidate agents comprise at least one anti-cancer agent.

### Claim 89 (depends on 83)

The method of claim 83, wherein the evaluation comprises excising at least one portion of the tissue after introducing said one or more fluid agents.

### Claim 90 (depends on 83)

The method of claim 83, wherein the evaluation comprises imaging the tissue.

### Claim 91 (depends on 83)

The method of claim 83, wherein said inserting is performed with a needle array device.
